Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Ping-Ching Hsu to Helicobacter Infections

This is a "connection" page, showing publications Ping-Ching Hsu has written about Helicobacter Infections.

 
Connection Strength
  
 
 
6.089
  
  1. Hsu PI, Chen KY, Tai WC, Yang JC, Tsay FW, Liu YH, Chen CL, Lee CL, Yeh HZ, Kuo CH, Chuah SK, Lee HC, Shie CB, Shiu SI, Kao JY, Yamaoka Y, Graham DY, Wu DC. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.746
  2. Hsu PI, Tsay FW, Kao JY, Peng NJ, Chen YH, Tang SY, Kuo CH, Kao SS, Wang HM, Wu IT, Shie CB, Chuah SK, Wu DC. Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection. Helicobacter. 2021 Oct; 26(5):e12840.
    View in: PubMed
    Score: 0.667
  3. Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Chen YH, Tsai TJ, Wu DC, Tsai KW. Short-term and long-term impacts of Helicobacter pylori eradication with reverse hybrid therapy on the gut microbiota. J Gastroenterol Hepatol. 2019 Nov; 34(11):1968-1976.
    View in: PubMed
    Score: 0.578
  4. Hsu PI, Pan CY, Kao JY, Tsay FW, Peng NJ, Kao SS, Wang HM, Tsai TJ, Wu DC, Chen CL, Tsai KW. Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria. Helicobacter. 2018 Aug; 23(4):e12498.
    View in: PubMed
    Score: 0.536
  5. Chuah YY, Wu DC, Chuah SK, Yang JC, Lee TH, Yeh HZ, Chen CL, Liu YH, Hsu PI. Real-world practice and Expectation of Asia-Pacific physicians and patients in Helicobacter Pylori eradication (REAP-HP Survey). Helicobacter. 2017 Jun; 22(3).
    View in: PubMed
    Score: 0.490
  6. Hsu PI, Yamaoka Y, Goh KL, Manfredi M, Wu DC, Mahachai V. Helicobacter pylori Infection. Biomed Res Int. 2015; 2015:278308.
    View in: PubMed
    Score: 0.433
  7. Hsu PI, Wu DC, Chen WC, Tseng HH, Yu HC, Wang HM, Kao SS, Lai KH, Chen A, Tsay FW. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014 Oct; 58(10):5936-42.
    View in: PubMed
    Score: 0.410
  8. Hsu PI, Lai KH, Lin CK, Chen WC, Yu HC, Cheng JS, Tsay FW, Wu CJ, Lo CC, Tseng HH, Yamaoka Y, Chen JL, Lo GH. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005 Nov; 100(11):2387-92.
    View in: PubMed
    Score: 0.224
  9. Wu PJ, Tsay FW, Wu DC, Yang JC, Chuah SK, Chen KY, Chen CL, Lee CL, Shih CA, Liu YH, Shiu SI, Tai WC, Kuo CH, Lei WY, Kao SS, Tsai TJ, Feng IC, Koseki M, Hsu PI, Sheu MJ. Sequential changes of antibiotic resistances of Helicobacter pylori in Taiwan from 2019 to 2024. World J Gastroenterol. 2025 Oct 21; 31(39):111380.
    View in: PubMed
    Score: 0.223
  10. Hsu PI, Li CN, Tseng HH, Lai KH, Hsu PN, Lo GH, Lo CC, Yeh JJ, Ger LP, Hsiao M, Yamaoka Y, Hwang IR, Chen A. The interleukin-1 RN polymorphism and Helicobacter pylori infection in the development of duodenal ulcer. Helicobacter. 2004 Dec; 9(6):605-13.
    View in: PubMed
    Score: 0.210
  11. Wu YY, Tsai HF, Lin WC, Chou AH, Chen HT, Yang JC, Hsu PI, Hsu PN. Helicobacter pylori enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in human gastric epithelial cells. World J Gastroenterol. 2004 Aug 15; 10(16):2334-9.
    View in: PubMed
    Score: 0.205
  12. Lin CH, Hsu PI, Tseng CD, Chao PJ, Wu IT, Ghose S, Shih CA, Lee SH, Ren JH, Shie CB, Lee TF. Application of artificial intelligence in endoscopic image analysis for the diagnosis of a gastric cancer pathogen-Helicobacter pylori infection. Sci Rep. 2023 08 17; 13(1):13380.
    View in: PubMed
    Score: 0.192
  13. Chuah YY, Wu DC, Chuah SK, Chen KY, Yang JC, Lee CL, Chen CL, Shiu SI, Shie CB, Shih CA, Tsay FW, Liu YH, Hsu PI. REAP-HP survey 2020: Comparing the real-world practice and expectation in Helicobacter pylori eradication of the Taiwanese gastroenterologists in 2015 and 2020. Helicobacter. 2022 Dec; 27(6):e12931.
    View in: PubMed
    Score: 0.180
  14. Chang YL, Tung YC, Tu YK, Yeh HZ, Yang JC, Hsu PI, Kim SE, Wu MF, Liou WS, Shiu SI. Efficacy of second-line regimens for Helicobacter pylori eradication treatment: a systemic review and network meta-analysis. BMJ Open Gastroenterol. 2020 09; 7(1).
    View in: PubMed
    Score: 0.156
  15. Cheng HC, Liou JM, Luo JC, Chiu CT, Wu MS, Lee YC, Wu CY, Wu DC, Hsu PI, Chang CC, Chang WL, Lin JT, Sheu BS. The implementation of the consensus on the management of Helicobacter pylori and barriers to consensus. Helicobacter. 2018 Oct; 23(5):e12533.
    View in: PubMed
    Score: 0.136
  16. Sheu BS, Wu MS, Chiu CT, Lo JC, Wu DC, Liou JM, Wu CY, Cheng HC, Lee YC, Hsu PI, Chang CC, Chang WL, Lin JT. Consensus on the clinical management, screening-to-treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter. 2017 Jun; 22(3).
    View in: PubMed
    Score: 0.121
  17. Kuo SH, Chen LT, Lin CW, Yeh KH, Shun CT, Tzeng YS, Liou JM, Wu MS, Hsu PN, Cheng AL. Expressions of the CagA protein and CagA-signaling molecules predict Helicobacter pylori dependence of early-stage gastric DLBCL. Blood. 2017 01 12; 129(2):188-198.
    View in: PubMed
    Score: 0.120
  18. Wang JW, Hsu CN, Tai WC, Ku MK, Hung TH, Tseng KL, Yuan LT, Nguang SH, Liang CM, Yang SC, Wu CK, Hsu PI, Wu DC, Chuah SK. The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases. PLoS One. 2016; 11(10):e0164824.
    View in: PubMed
    Score: 0.120
  19. Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial. J Antimicrob Chemother. 2013 Jan; 68(1):222-8.
    View in: PubMed
    Score: 0.090
  20. Wu DC, Hsu PI, Tseng HH, Tsay FW, Lai KH, Kuo CH, Wang SW, Chen A. Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies. Medicine (Baltimore). 2011 May; 90(3):180-185.
    View in: PubMed
    Score: 0.082
  21. Hsu PI, Jwo JJ, Yang CL, Hsu PN, Yang HB, Lai KH, Chen IS, Chuah SK, Wu DC, Chen A. Association of the myeloperoxidase polymorphism with the risk of gastric cancer. Anticancer Res. 2008 Mar-Apr; 28(2B):1317-23.
    View in: PubMed
    Score: 0.066
  22. Lo GH, Yu HC, Chan YC, Chen WC, Hsu PI, Lin CK, Lai KH. The effects of eradication of Helicobacter pylori on the recurrence of duodenal ulcers in patients with cirrhosis. Gastrointest Endosc. 2005 Sep; 62(3):350-6.
    View in: PubMed
    Score: 0.055
  23. Wu CJ, Hsu PI, Lo GH, Lo CC, Lin CK, Shie CB, Peng NJ, Tseng HH, Jou HS, Tsai PM, Chen A, Chen JL, Lai KH. Comparison of cetraxate-based and pantoprazole-based triple therapies in the treatment of Helicobacter pylori infection. J Chin Med Assoc. 2004 Apr; 67(4):161-7.
    View in: PubMed
    Score: 0.050
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.